Lyndsay N. Harris|Nofisat Ismaila|Lisa M. McShane|Andrea Varga|Deborah Collyar|Ana María González-Angulo|Elizabeth H. Hammond|Nicole M. Kuderer|Minetta C. Liu|Robert G. Mennel|Catherine Van Poznak|Robert C. Bast|Daniel F. Hayes
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
American Society of Clinical Oncology|Case Western Reserve University|Intermountain Healthcare|American Society of Clinical Oncology|Case Western Reserve University|Intermountain Healthcare|American Society of Clinical Oncology|Case Western Reserve University|Intermountain Healthcare|American Society of Clinical Oncology|Case Western Reserve University|Intermountain Healthcare|American Society of Clinical Oncology|Case Western Reserve University|Intermountain Healthcare|American Society of Clinical Oncology|Case Western Reserve University|Intermountain Healthcare|American Society of Clinical Oncology|Case Western Reserve University|Intermountain Healthcare|American Society of Clinical Oncology|Case Western Reserve University|Intermountain Healthcare|American Society of Clinical Oncology|Case Western Reserve University|Intermountain Healthcare|American Society of Clinical Oncology|Case Western Reserve University|Intermountain Healthcare|American Society of Clinical Oncology|Case Western Reserve University|Intermountain Healthcare|American Society of Clinical Oncology|Case Western Reserve University|Intermountain Healthcare|American Society of Clinical Oncology|Case Western Reserve University|Intermountain Healthcare
purpose provide recommendations appropriate use breast tumor biomarker assay results guide decisions adjuvant systemic therapy women earlystage invasive breast cancer methods literature search prospectively defined study selection sought systematic reviews metaanalyses randomized controlled trials prospectiveretrospective studies prospective comparative observational studies published 2006 2014 outcomes interest included overall survival diseasefree recurrencefree survival expert panel members used informal consensus develop evidencebased guideline recommendations results literature search identified 50 relevant studies one randomized clinical trial 18 prospectiveretrospective studies found evaluated clinical utility defined guideline specific biomarkers guiding decisions need adjuvant systemic therapy studies met guideline criteria clinical utility found guide choice specific treatments regimens recommendations addition estrogen progesterone receptors human epidermal growth factor receptor 2 panel found sufficient evidence clinical utility biomarker assays oncotype dx endopredict pam50 breast cancer index urokinase plasminogen activator plasminogen activator inhibitor type 1 specific subgroups breast cancer biomarker except estrogen receptor progesterone receptor human epidermal growth factor receptor 2 found guide choices specific treatment regimens treatment decisions also consider disease stage comorbidities patient preferences